Demystify Meds for Moderate to Severe Crohn’s Disease
August 2023
We’re getting questions about how to manage moderate to severe Crohn’s disease...due to a new indication for upadacitinib (Rinvoq).
Continue to use shared-decision making and lean toward a “top-down” approach...with earlier use of biologics before steroid dependence or disease progression. And work closely with GI colleagues.
Biologics include TNF-alpha blockers (adalimumab, etc)...anti-interleukin meds (ustekinumab, etc)...and selective adhesion blockers (vedolizumab, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote